Subscribe

Advertisement

TRIAL SNAPSHOT

Acronym: EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

  • PHASE:
    2
  • NCT#:
    NCT00000000
  • STATUS:
    Not yet recruiting
  • START DATE:
    00/00/0000
  • LOCATION:
    United States, New York, NY
  • END DATE:
    00/00/0000
  • GENERIC DRUG NAME:
    Drug Name Here



Investigators

TRIAL ARTICLES

MORE TRIAL ARTICLES

Latest Conferences

VIEW ALL

ASCO-GI 2023

Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancery

In publishing and graphic design, Lorem ipsum is a placeholder text commonly used to demonstrate the visual form.

May 08, 2023
ASCO-GU 2023

Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancery

In publishing and graphic design, Lorem ipsum is a placeholder to demonstrate the visual form of a document or a typeface

May 08, 2023
ASCO-GC 2023

Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancery

Lorem ipsum is a placeholder text commonly used to demonstrate the visual form of a document or a typeface

May 08, 2023

RELATED CONTENT

VIEW ALL

No Results Found

The posts you requested could not be found. Try changing your module settings or create some new posts.

Advertisement

Advertisement

Advertisement